Head of Global Pharmaceuticals and European Healthcare
Mr. Hill joined Greenhill in 2012 and focuses on the healthcare sector. He has recently advised on landmark transactions such as Teva's USD42bn acquisition of Allergan's generics business and Actavis' USD28bn acquisition of Forest Laboratories and USD8bn acquisition of Warner Chilcott. He previously served as Head of Healthcare for EMEA and Asia-Pacific at Bank of America Merrill Lynch, having joined Merrill Lynch in 2000. During his twelve years there he advised on some of the largest healthcare transactions in Europe and the Emerging Markets. Prior to joining Merrill Lynch, he spent five years at Charterhouse Bank and three years at Price Waterhouse, where he qualified as a Chartered Accountant. Rupert speaks fluent French and Spanish.